logo
Even old brains can make new neurons, study suggests

Even old brains can make new neurons, study suggests

Yahoo03-07-2025
Your body is constantly generating new cells. In your digestive tract, the colon's lining turns over every five to seven days. Your red blood cells replace themselves every few weeks, skin cells about once a month. But certain organs are a big exception. Contrary to popular belief, we are not biological Theseus' ships, reconstructing ourselves entirely from fresh building blocks every seven years. Most of your neurons, the cells that fast-track information across the brain, spine, and sensory organs, have the same lifespan as you do. Until the late 20th century, the prevailing view in neuroscience was that, past childhood, humans stop making neurons, brain-wide. What we have in adolescence, is what we get, and all we can do is lose cells or reorganize them. However, the latest research adds to a mounting body of evidence finding that the timeline of neuron generation isn't so clear-cut.
In at least two parts of the brain, a subset of neuroscientists believe that neurons may continue to form throughout life–the hippocampus and the ventral striatum. In the hippocampus, a critical brain region for learning and memory, new cells emerge in some people into late adulthood, according to a study published July 3 in the journal Science. The findings tip the scales in a still-active debate over how our brains continue to develop throughout life. A better understanding of adult neurogenesis (the formation of new neurons), and a firm answer to if and where it occurs, could help improve treatments for neurological diseases as well as normal aging.
[ Related: Scientists mapped every neuron of an adult animal's brain for the first time. ]
Past research in rodents, pigs, and monkeys has shown that neurogenesis does happen in these other mammals, throughout life. Birds do it too. Yet based on other noted structural and developmental differences in the human brain, some scientists argue that our species is unique and lacks the lifelong neurogenesis that might interrupt complex, streamlined brain function. (New neurons may sound great, but too much activity and connectivity can cause chaos.) And it's difficult to get a clear answer. It's a major technical challenge to pin down new brain cells in humans because you can't readily see through living skulls at the cellular level. Researchers largely have to rely on scarce brain tissue collected via surgery on those with medical conditions like epilepsy or tissue donated by the deceased.
With this new study, 'I think they used really strong tools,' Mercedes Paredes, a neurologist and developmental neuroscientist at University of California, San Francisco, tells Popular Science. Paredes was not involved in the research, but has previously found contrasting results in her own lab. The new work, she says, is a 'good starting point' for applying novel methods to the brain and deciphering what types of cells are truly present.
Other studies of potential adult neurogenesis have looked at protein and immune signatures in brain tissues to determine if, where, and how often new neurons are being formed. They've come to conflicting conclusions, with some (like Paredes' 2018 work) failing to identify the cells that other researchers report seeing. There've also been a few studies that rely on carbon dating to ascertain the age of neurons, which find young cells in adults. However, none of these methods have, so far, reliably pinpointed the stem cells or progenitors capable of yielding fresh neurons–leaving room for doubt.
The new study seems to address this previously unresolved point. It's the 'missing link' of neurogenesis, Jonas Frisén, senior study author and a developmental biologist and stem cell researcher at Karolinska Institutet in Stockholm, tells Popular Science. To find that missing link, Frisén and his co-authors surveyed the scientific literature to compile a list of genes that are likely active in hippocampal neurogenesis. Then, they confirmed those gene markers (largely from animal studies) by comparing them to RNA sequences found in brain samples from six deceased, child and infant donors. Next, the team sequenced RNA from mitochondria in the brain tissue from 19 people between the ages of 13 and 78. They used three different machine learning algorithms to assess those sequences and identify likely intermediate, forming neural cells. The scientists validated their machine learning outputs by applying the same tools to datasets from mice and adult human cortex cells, and reported a false positive rate of just 0.37 percent.From all of their analyses, they identified 354 of cells out of hundreds of thousands across their 19 samples that appeared to be precursors to new neurons, including dozens of stem cells and neuroblasts from adults. The cells weren't distributed uniformly, only showing up in half the adolescent samples and five of the 14 adult samples. However, whether or not the cells were present didn't seem to wholly correlate with age or documented disease. One of the adults with the highest number of neurogenesis-related cells present was a 58-year-old with no known pathology, per the study.'We nailed down active neurogenesis in the adult human brain,' Marta Paterlini, a neuroscientist at Karolinska Institutet, tells Popular Science. She co-led the new work over eight years alongside her colleague Ionut Dumitru, who focused on the machine learning side. 'We are confident in our data,' Paterlini says. 'We would like to put an end to the controversy.'
Still, not everyone in the field agrees that the cells identified in this study are indisputably emerging adult neurons. 'When I first heard about this study, I was excited. It's the sort of approach you would want to use to ID rare subtypes,' Shawn Sorrells, a neuroscientist at the University of Pittsburgh who co-authored the 2018 study with Paredes, tells Popular Science.
But, after a closer look, he was 'disappointed by how few cells they found,' and in his view, there's an alternate potential explanation.
'The most likely conclusion is that the cells they are looking for are rare or nonexistent in most people. The other possibility is that the cells they claim are adult neural stem cells are associated with a disease process in these individuals or some other cell type altogether.'
The human brain is full of cells that do divide and replicate throughout life called glial cells. These are the supportive and connective cells that enable neurons to do the job of conveying nerve signals. Glial cells are neurons' pit crew. It's possible that, in their efforts to identify neurons in progress, the study authors may have inadvertently included some glial stem cells in their analysis, Sorrells suggests.
[ Related: New human brain atlas is the most detailed one we've seen yet. ]
Both Sorrells and Paredes believe more research is needed to confirm the new study's conclusions. Direct, morphological comparisons between human and animal cells could boost the findings, says Paredes. Sorrells suggests we'll need more advanced brain imaging techniques to really resolve the issue.
'Following the same cells over time to see how they develop. That will be the best evidence for neurogenesis,' he explains, though notes that's currently not possible.
And so, the science presses on. If, as the new research indicates, some healthy humans do continue to make neurons inside their hippocampuses for life, it could have major implications for psychiatric and neurodegenerative diseases like Alzheimers, where animal studies indicate a dearth of new cells plays a role. It could also aid in our ability to understand and maximize healthy aging and neuroplasticity, Frisén says.
Perhaps down the line, adult neural stem cells could be used to help people recover after brain trauma, Paterlini suggests. 'The lab is working on regenerative medicine, so we will keep going on this.' And maybe all their effort will manage to change minds about how much human minds can change.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tallahassee's Kearney Center launches in-house medical care
Tallahassee's Kearney Center launches in-house medical care

Yahoo

time23 minutes ago

  • Yahoo

Tallahassee's Kearney Center launches in-house medical care

The Kearney Center has officially opened its new on-site medical center, aimed to provide health care to residents. The center teamed up with Doctors United Group, a non-profit organization committed to supporting underserved individuals, for the facility, which officially opened Aug. 1. News was shared with the Tallahassee Democrat back in May by Kearney Center CEO Sonya Wilson. She spoke on the importance of having in-house support. "They will be a big provider in the area for our underserved population ... that's going to save the community an immense amount of money by providing the primary care here," Wilson said in May. Residents will now be offered in-house primary care. Basic medical care may include check-ups, immunizations, mental healthcare and more, whether patients are uninsured or not. The Kearney Center will be hosting a grand opening for the medical center at 10 a.m. on Aug. 22. Arianna Otero is the trending and breaking news reporter for the Tallahassee Democrat. Contact her via email at AOtero@ and follow her on X: @ari_v_otero. This article originally appeared on Tallahassee Democrat: Kearney Center in Tallahassee opens new on-site medical center Play Farm Merge Valley

Are you aware if the food you're eating is ultra-processed? The answer could make all the difference for your health
Are you aware if the food you're eating is ultra-processed? The answer could make all the difference for your health

CBS News

time29 minutes ago

  • CBS News

Are you aware if the food you're eating is ultra-processed? The answer could make all the difference for your health

An alarming look at the foods consumed by families across America: A recent study from the Centers for Disease Control and Prevention (CDC) reveals that most Americans get more than half of their daily calories from ultra-processed foods, and that's leading to some serious health issues. CBS News Miami visited a South Florida family's kitchen with a nutritionist to gather information that can help you live a better life. Katrina and Charles Winters spend a lot of time in their kitchen. They homeschool their daughter, preparing all her daily meals and run a meal service for their employees. "Most of our food is pretty natural, whole food," said Katrina Winters. "I would say that we do have a snack cabinet that we keep pretty stocked for our daughter, also, I take her to school and I need to have things I can just grab and go in the car." "I travel a lot, so we do have to eat out quite a lot but when we are home we are cooking a most of our meals here," added Charles Winters. Founder of Essence Nutrition, dietitian Monica Auslander-Moreno, examined their pantry and refrigerator to highlight what they're doing well and areas for improvement. "This is a processed food; there is nothing that has been added to these hazel nuts, so that's great, but someone had to put them in this bag and that's okay," said Auslander-Moreno. "These are peanut butter and jelly dippers; this would be an ultra-processed food. It doesn't necessarily mean that I wouldn't eat them, but we would define them as a UPF," she continued. Ultra-processed foods (UPFs) are typically low in fiber and high in salt, sweeteners and unhealthy fats. The most common offenders include burgers, sandwiches, sweet baked goods, savory snacks, pizza and sweetened beverages. "The concern is that we are displacing the whole foods, the fruits and vegetables. Or the lightly processed foods, like the lightly frozen fruits and vegetables, and we are going to suffer from completely preventable diseases as a result of consuming these ultra-processed foods," Auslander-Moreno said. Studies have associated these types of foods with obesity, type 2 diabetes and heart disease. According to the new CDC report, from August 2021 to August 2023, individuals aged one year and older consumed an average of 55% of their total calories from ultra-processed foods. Children aged 1-18 consumed an even higher percentage, at 61.9%, compared to adults 19 and older, who averaged 53% CBS News Miami's nutrition expert emphasized that children often emulate their parents' behavior, as displayed by 5-year-old Jaco and his little brother, who can easily list their favorite healthy foods. "Cucumbers, avocados, and hearts of palm and chicken," Jaco exclaimed. "Hahah yeah, chicken." Auslander-Moreno told CBS News Miami that she asks people two questions to help them determine whether they're eating an ultra-processed food. "Two rules, so I ask people if their great, great, great grandmother or grandfather would recognize this food as indeed being food and if they could define that for you," she said. "[And] I would ask them if I give them all the food categories based on the MyPlate recommendations, 'Where would you put this food? Is it a fruit, is it a vegetable, how would you categorize it?' and then lastly, tell me where this food grew in the earth, or walked on the earth or swam in the ocean, and if those are really challenging questions to answer, it's likely a UPF." Auslander-Moreno shared her suggestions on how to replace common ultra-processed foods in your diet: Instead of hamburgers with frozen beef patties: Consider a salmon burger, cook it with olive oil and add lots of vegetables. Instead of sodas, opt for: Sparkling waters. You can also muddle cucumbers and citrus infuse them into sparkling or plain water. And instead of baked goods: Try baked apples with cinnamon. While technically baked, it's simply fruit with spice and satisfies that pie craving. You can top it with nuts or plain Greek yogurt. Experts also said to be cautious of products that seem healthy based solely on their packaging. Learn to read labels closely, and if you see an ingredient you don't recognize, research it to understand what you're consuming.

Tenet (THC) Up 14.9% Since Last Earnings Report: Can It Continue?
Tenet (THC) Up 14.9% Since Last Earnings Report: Can It Continue?

Yahoo

time38 minutes ago

  • Yahoo

Tenet (THC) Up 14.9% Since Last Earnings Report: Can It Continue?

It has been about a month since the last earnings report for Tenet Healthcare (THC). Shares have added about 14.9% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Tenet due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent drivers for Tenet Healthcare Corporation before we dive into how investors and analysts have reacted as of late. Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View Tenet Healthcare reported second-quarter 2025 adjusted earnings per share (EPS) of $4.02, which surpassed the Zacks Consensus Estimate by 41.6%. The bottom line soared 74% year over year. Net operating revenues advanced 3.2% year over year to $5.3 billion. The top line beat the consensus mark by 2.4%. The company's quarterly results were aided by higher same facility revenues, favorable payer mix and improved acuity, which led to strong performance of the Hospital Operations and Services segment. Facility buyouts buoyed the performance of the Ambulatory Care segment. However, the upside was partly offset by rising operating costs—particularly supplies expense. THC's Q2 Performance Adjusted net income of $369 million climbed 63.3% year over year in the quarter under review. Adjusted EBITDA improved 18.6% year over year to $1.1 billion, higher than our estimate of $997 million. The year-over-year growth resulted from improved same facility revenues, higher acuity, favorable payer mix and prudent expense management efforts. Adjusted EBITDA margin of 21.3% improved 280 basis points (bps) year over year. Total operating costs increased 2.3% year over year to $4.5 billion in the second quarter due to a higher supplies expense. Segmental Details Hospital Operations and Services: The segment recorded net operating revenues of $4 billion, which inched up 0.9% year over year on the back of improved same hospital admissions, higher acuity and favorable payer mix. The metric beat the Zacks Consensus Estimate of $3.92 billion and our estimate of $3.89 billion. Nevertheless, on a same-hospital basis, net patient service revenues grew 5.6% year over year. Adjusted EBITDA climbed 25.1% year over year to $623 million in the second quarter resulting from higher same facility revenues, favorable payer mix and prudent expense management efforts. The metric outpaced the consensus mark of $505 million and our estimate of $480.6 million. Adjusted EBITDA margin of 15.6% improved 300 bps year over year. Ambulatory Care: The segment's net operating revenues rose 11.3% year over year to $1.3 billion in the quarter under review on the back of improved net revenue per case growth, facility buyouts and expansion of service lines. The metric outpaced the Zacks Consensus Estimate of $1.23 billion and our estimate of $1.24 billion. Adjusted EBITDA was $498 million, which advanced 11.4% year over year, attributable to facility buyouts and solid net revenue per case growth. The metric beat the consensus mark of $496 million but fell short of our estimate of $516.3 million. Adjusted EBITDA margin remained flat year over year at 39.2%. THC's Financial Position (as of June 30, 2025) Tenet exited the second quarter with cash and cash equivalents of $2.6 billion, which declined 13.1% from the 2024-end level. Total assets of $28.7 billion dipped 0.8% from the figure at 2024-end. Long-term debt, net of the current portion, amounted to $13.1 billion, which inched up marginally from the figure as of Dec. 31, 2024. The current portion of long-term debt totaled $84 million. Total shareholders' equity of $3.7 billion decreased 10.1% from the 2024-end level. THC generated $1.8 billion of net cash from operations in the first half of 2025, which advanced 31.4% year over year. Free cash flows improved 23.4% year over year to $743 million. THC's Share Repurchase Update THC bought back common shares worth $747 million in the second quarter of 2025. Management sanctioned an increase of $1.5 billion to the share repurchase program. As of July 22, 2025, the company had a leftover share repurchase authorization of $1.8 billion. Tenet's Outlook 3Q25 THC expects third-quarter 2025 adjusted EBITDA to be 22.5-23.5% of its full-year 2025 adjusted EBITDA guided range. 2025 Net operating revenues are currently within $20.95-$21.25 billion, higher than the earlier view of $20.6-$21 billion. The midpoint of the revised guidance indicates 2.1% growth from the 2024 figure. Net operating revenues of the Hospital segment are forecasted to lie between $15.95 billion and $16.1 billion, higher than the prior guidance of $15.75-$16 billion. The midpoint of the updated outlook indicates a 0.7% decline from the 2024 figure. The metric at the Ambulatory Care unit is estimated within $5-$5.15 billion, up from the previous view of $4.85-$5 billion. The midpoint of the revised guidance implies 11.9% growth from the 2024 figure. Adjusted EBITDA is likely to remain between $4.4 billion and $4.54 billion for 2025, higher from the prior view of $3.975-$4.175 billion. The midpoint of the updated guidance indicates 11.9% growth from the 2024 figure. Adjusted EBITDA margin is estimated to be in the 21-21.4% band compared with the earlier view of 19.3-19.9%. Adjusted net income is projected between $1.415 billion and $1.475 billion, up from the prior outlook of $1.115-$1.220 billion. Adjusted EPS is presently anticipated within $15.55-$16.21, up from the earlier view of $11.99-$13.12. The mid-point of the revised outlook implies a 33.7% rise from the 2024 figure. Interest expense is currently estimated between $815 million and $825 million. Net cash provided by operating activities is expected between $2.75 billion and $3.1 billion. Free cash flow is estimated to remain between $2.025 billion and $2.275 billion. Capital expenditures are projected in the range of $725-$825 million. How Have Estimates Been Moving Since Then? It turns out, fresh estimates have trended upward during the past month. The consensus estimate has shifted 33.86% due to these changes. VGM Scores Currently, Tenet has a average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a score of A on the value side, putting it in the top quintile for value investors. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Outlook Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Tenet has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store